Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Roche & Tecentriq.
View:
Post by fox7mf on Sep 27, 2023 9:15am

Roche & Tecentriq.

I don't know if it was a slip, but Matt said Tecentriq will be the CI used in the trial with PanCan. Cmon Roche, time to acquire!!!
Comment by Lesalpes29 on Sep 27, 2023 9:21am
What is the probability of a slip? Can they use it without Roch as a partner? I'm lost! GLTAL 
Comment by Noteable on Sep 27, 2023 9:55am
As I previously stated "think" the upcoming release of GOBLET Phase 2 clinical trial using data with Roche's CPI Tecentriq followed by the potential of Accelerated Approval with PanCan Precision Promise Phase 3 trial using Roche's Tecentriq as the confirmatory trial that satisfies the FDA's post approval requirements. The upcoming PanCan Precision Promise Phase 3 trial with ...more  
Comment by Noteable on Sep 28, 2023 3:02pm
As I previously stated the upcoming release of GOBLET Phase 2 clinical trial using data with Roche's CPI Tecentriq is the set up for the potential of granting of an FDA Accelerated Approval with PanCan Precision Promise Phase 3 trial using Roche's Tecentriq as the confirmatory trial, pursuant to the FDA's post approval requirements. The upcoming PanCan ...more  
Comment by Buckhenry on Sep 27, 2023 12:26pm
Them fireside chats do wonders for the stock... please continue to be patient...
Comment by Azzak34 on Sep 27, 2023 12:42pm
Again, great points!!! News is amazing..... sell, sell, sell. 
Comment by Quentin30 on Sep 27, 2023 1:33pm
must have been an eartyh shattering presentation for ONCY to be up 0.1%...  hope you bought more Azzak... this is going to the moon, with absolute certainty... LOL... 
Comment by Azzak34 on Sep 27, 2023 1:35pm
You must check your spelling before posting. eartyh is not a place I've ever heard of. 
Comment by Quentin30 on Sep 27, 2023 2:08pm
thanks for pointing that out... earth... I dare say you haven't heard of that either, since you clearly live in cloud cuckooland.
Comment by Azzak34 on Sep 27, 2023 2:24pm
Just trying to help. When you talk absoloute garbage, the last thing you need is poor spelling to compound the nonsense. 
Comment by Quentin30 on Sep 27, 2023 2:58pm
You're absolutely right about me talking garbage... since I did state this is going to the moon... Thanks for pointing out the futility of being a pumper...
Comment by Azzak34 on Sep 27, 2023 3:06pm
Quentin30..... "Maybe the guy ingested something that cured his Pancreatic Cancer, or it was a placebo effect or something". I'm bringing this up weekly from now on. You actually said this. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities